ADAC Laboratories continues to roll smoothly. The Milpitas, CA, nuclear medicine company last week released second-quarter financial results that showed revenues climbing 20% and net income increasing 44%.For the quarter (end-March), the company posted
ADAC Laboratories continues to roll smoothly. The Milpitas, CA, nuclear medicine company last week released second-quarter financial results that showed revenues climbing 20% and net income increasing 44%.
For the quarter (end-March), the company posted sales of $70 million, compared with $58.4 million in the same period the year before. ADAC's product revenue climbed 23%, while its service revenue grew 10%, the company said.
ADAC's net income was $5.6 million, compared with $3.9 million in the second quarter of 1996. ADAC's stock climbed 6% on April 24, the day the financials were announced, to close at $17 a share, up one point. The stock rose again on April 25 and closed at $19.50.
In other ADAC news, the company announced the results of clinical trials for Vantage ExSPECT, a new-generation version of its Vantage attenuation correction technique. In a paper presented at the International Conference of Nuclear Cardiology in Florence, Italy, researchers said that Vantage ExSPECT could lead to a reduction in false positives in cardiac imaging scans.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.